Advertisement
Advertisement
U.S. markets open in 4 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Pherecydes Pharma Société anonyme (ALPHE.PA)

Paris - Paris Delayed Price. Currency in EUR
2.3600+0.0600 (+2.61%)
As of 10:47AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close2.3000
Open2.3300
BidN/A x N/A
AskN/A x N/A
Day's Range2.2900 - 2.3850
52 Week Range1.8600 - 6.9490
Volume1,320
Avg. Volume3,515
Market Cap16.978M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ALPHE.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Pherecydes Pharma Announces Its Participation in Several Scientific and Investor Conferences

      NANTES, France, January 25, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, announced today that its management team will participate in the following scientific and investor events:

    • Business Wire

      Pherecydes Pharma Announces its Financial Agenda for 2023

      NANTES, France, January 03, 2023--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announced its financial agenda for 2023.

    • Business Wire

      Pherecydes Pharma: Minutes of the Combined General Meeting of December 15, 2022

      NANTES, France, December 15, 2022--Regulatory News: Pherecydes Pharma (FR0011651694 - ALPHE, eligible for PEA-PME equity savings plans) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces that the Combined General Meeting of December 15, 2022 was able to deliberate, the quorum having been reached.

    Advertisement
    Advertisement